Research on the eventual enzymatic induction activity of cetiedil in rat and man.
Therapeutic consequences of the enzyme induction phenomenon are briefly reminded. This action was investigated: 1.--In the rat: by measuring the P450 Cytochrome content of hepatic microsomes in rats treated with Cetiedil. The results were compared with those obtained with controlled rats in similar conditions who had received either phenobarbital or no drugs at all. 2.--In man: by measuring the urinary elimination of D-glucaric acid and by measuring the plasma half-life of antipyrine before and after Cetiedil. These results in man were compared with similar results obtained before and after treatment with Rifampicin. Cetiedil does not seem to produce any increase in hepatic enzyme activity.
D000328:Adult; D000368:Aged; D000818:Animals; D000983:Antipyrine / Q000378:metabolism; D001381:Azepines / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004790:Enzyme Induction / Q000187:drug effects*; D005260:Female; D005937:Glucaric Acid / Q000652:urine; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D011506:Proteins / Q000378:metabolism; D051381:Rats; D012293:Rifampin / Q000494:pharmacology; D013045:Species Specificity; D013876:Thiophenes / Q000494:pharmacology*
D001381:Azepines; D011506:Proteins; D013876:Thiophenes; C006955:cetiedil; D003577:Cytochrome P-450 Enzyme System; D005937:Glucaric Acid; D000983:Antipyrine; D012293:Rifampin